Novartis AG Share Price Swiss Exchange
Stocks
CH0012005267
Pharmaceuticals
OTC Markets Traded|
Real-time Estimate
Cboe Europe
16:20:00 03/09/2026 BST
|
||
| 131.76 CHF | 0.00% |
|
| Market Cap | 307B 264B 248B 227B 423B 29,034B 427B 2,934B 1,142B 14,837B 1,153B 1,128B 47,785B | P/E 2026 * |
22.9x | P/E 2027 * | 19.5x |
|---|---|---|---|---|---|
| Enterprise Value | 340B 292B 274B 251B 469B 32,123B 472B 3,246B 1,264B 16,416B 1,276B 1,248B 52,870B | EV / Sales 2026 * |
5.89x | EV / Sales 2027 * | 5.46x |
| Free-Float |
91.66% | Yield 2026 * |
2.7% | Yield 2027 * | 2.82% |
Last Transcript : Novartis AG
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 50 | 31/01/2018 | |
Mukul Mehta
DFI | Director of Finance/CFO | - | 15/03/2026 |
Karen Hale
CMP | Compliance Officer | 58 | 13/04/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Nancy Andrews
BRD | Director/Board Member | 67 | 31/12/2014 |
| Director/Board Member | 69 | 31/12/2015 | |
Ton Büchner
BRD | Director/Board Member | 61 | 31/12/2015 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.22% | -1.30% | +57.33% | +107.97% | 1,034B | |
| +1.18% | +4.78% | +56.45% | +73.31% | 663B | |
| -0.20% | +1.26% | +23.38% | +78.92% | 462B | |
| +2.09% | -2.06% | +32.28% | +38.37% | 344B | |
| 0.00% | +5.36% | +27.40% | +47.50% | 307B | |
| +1.42% | +0.26% | -0.52% | +13.62% | 251B | |
| +0.15% | +1.49% | +56.25% | +74.60% | 239B | |
| -0.03% | +2.13% | -17.30% | -53.99% | 207B | |
| +0.94% | +1.23% | +33.36% | +100.49% | 186B | |
| Average | +0.79% | -0.70% | +29.85% | +53.42% | 410.37B | |
| Weighted average by Cap. | +0.70% | -0.84% | +38.72% | +68.58% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 57.65B 49.6B 46.55B 42.59B 79.49B 5,450B 80.11B 551B 214B 2,785B 216B 212B 8,969B | 61.31B 52.75B 49.5B 45.29B 84.53B 5,796B 85.2B 586B 228B 2,962B 230B 225B 9,539B |
| Net income | 13.95B 12B 11.26B 10.31B 19.24B 1,319B 19.39B 133B 51.89B 674B 52.39B 51.25B 2,171B | 15.5B 13.34B 12.52B 11.45B 21.37B 1,465B 21.54B 148B 57.66B 749B 58.21B 56.94B 2,412B |
| Net Debt | 32.68B 28.12B 26.39B 24.14B 45.06B 3,089B 45.42B 312B 122B 1,579B 123B 120B 5,084B | 27.82B 23.93B 22.46B 20.55B 38.35B 2,630B 38.66B 266B 103B 1,344B 104B 102B 4,328B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Select your edition
All financial news and data tailored to specific country editions
